ProfileGDS5678 / 1433986_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 85% 83% 83% 83% 83% 84% 84% 84% 84% 84% 85% 83% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2277784
GSM967853U87-EV human glioblastoma xenograft - Control 26.4400485
GSM967854U87-EV human glioblastoma xenograft - Control 36.0902583
GSM967855U87-EV human glioblastoma xenograft - Control 46.2951983
GSM967856U87-EV human glioblastoma xenograft - Control 56.0882383
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.84983
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0429584
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1364484
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2734984
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2261984
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2245784
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.45285
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0681983
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2459884